Novo Nordisk taps Evotec to target chronic kidney disease

Novo Nordisk taps Evotec to target chronic kidney disease

Source: 
Fierce Biotech
snippet: 

Novo Nordisk has signed up to work with Evotec on the discovery and development of chronic kidney disease (CKD) drugs. The deal comes two years after Novo Nordisk licensed a kidney disease prospect from Epigen Biosciences as part of its effort to expand into areas adjacent to its core diabetes business.